Taiho Oncology, Inc.
Angela Hu, Ph.D. has a diverse work experience in the pharmaceutical industry. Angela is currently working at Taiho Oncology, Inc. as the Executive Director and Head of Global Regulatory Affairs Strategy. Prior to this, they held the role of Senior Director of Global Regulatory Affairs Strategy at the same company.
Before joining Taiho Oncology, Inc., Angela worked as the Director and Head of Global Regulatory Affairs Strategy and Operations at Luye Pharma USA Ltd. Angela also held the position of Director of Global Regulatory Affairs at Symphogen.
Angela has a strong background in regulatory affairs and translational medicine. Angela worked as the Associate Director of Regulatory Affairs Strategy at Pacira BioSciences, Inc. and as the Director of Regulatory Affairs and Translational Medicine at Hengrui Therapeutics, Inc.
Earlier in their career, Angela worked at Eli Lilly where they held multiple roles, including Senior Research Scientist in Oncology Discovery and Research Scientist in Functional Genomics. Angela also worked as a Postdoctoral Fellow in Cardiovascular Research.
Overall, Angela Hu, Ph.D. has a wealth of experience in global regulatory affairs strategy and operations in the pharmaceutical industry.
Angela Hu, Ph.D. holds a Ph.D. in Molecular and Cell Biology from The University of Texas at Dallas. Prior to that, they obtained a B.S. in Biochemistry from Nankai University. No specific start or end years are provided for either of the degrees.
This person is not in any teams
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com